| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspergillus fumigatus | 15 | 2025 | 52 | 4.750 |
Why?
|
| Phagosomes | 11 | 2019 | 54 | 3.240 |
Why?
|
| Lectins, C-Type | 11 | 2023 | 89 | 3.180 |
Why?
|
| Candida albicans | 14 | 2025 | 71 | 2.600 |
Why?
|
| Macrophages | 15 | 2025 | 1033 | 2.380 |
Why?
|
| Research Personnel | 9 | 2025 | 94 | 2.200 |
Why?
|
| Physicians | 9 | 2025 | 468 | 2.080 |
Why?
|
| Neutrophils | 10 | 2024 | 375 | 2.070 |
Why?
|
| Candidiasis | 6 | 2024 | 50 | 1.950 |
Why?
|
| Immunity, Innate | 9 | 2025 | 790 | 1.880 |
Why?
|
| Toll-Like Receptor 9 | 5 | 2019 | 209 | 1.750 |
Why?
|
| beta-Glucans | 6 | 2018 | 56 | 1.710 |
Why?
|
| Kangai-1 Protein | 4 | 2019 | 7 | 1.670 |
Why?
|
| Mycoses | 4 | 2025 | 46 | 1.620 |
Why?
|
| Biomedical Research | 8 | 2025 | 267 | 1.540 |
Why?
|
| Aspergillosis | 6 | 2024 | 41 | 1.540 |
Why?
|
| Fungi | 4 | 2025 | 57 | 1.360 |
Why?
|
| Optical Tweezers | 3 | 2012 | 8 | 1.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2024 | 610 | 1.110 |
Why?
|
| Staphylococcus aureus | 7 | 2025 | 176 | 1.090 |
Why?
|
| Epithelial Cells | 7 | 2024 | 385 | 1.060 |
Why?
|
| Melanins | 2 | 2024 | 24 | 1.050 |
Why?
|
| Career Choice | 6 | 2025 | 131 | 1.050 |
Why?
|
| Dendritic Cells | 8 | 2018 | 520 | 1.040 |
Why?
|
| Mice | 41 | 2025 | 10751 | 1.030 |
Why?
|
| Reactive Oxygen Species | 4 | 2024 | 223 | 0.970 |
Why?
|
| Animals | 51 | 2025 | 20501 | 0.970 |
Why?
|
| Host-Pathogen Interactions | 5 | 2018 | 259 | 0.970 |
Why?
|
| Chemokine CXCL1 | 1 | 2024 | 6 | 0.900 |
Why?
|
| Humans | 82 | 2025 | 63003 | 0.880 |
Why?
|
| Interleukin-8 | 1 | 2024 | 88 | 0.870 |
Why?
|
| Adenine | 1 | 2024 | 50 | 0.860 |
Why?
|
| Piperidines | 1 | 2024 | 63 | 0.860 |
Why?
|
| Signal Transduction | 12 | 2024 | 3014 | 0.860 |
Why?
|
| Skin Diseases | 1 | 2024 | 81 | 0.830 |
Why?
|
| Dermatology | 1 | 2024 | 74 | 0.830 |
Why?
|
| Cell Wall | 3 | 2020 | 118 | 0.820 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 148 | 0.810 |
Why?
|
| Internal Medicine | 5 | 2025 | 160 | 0.800 |
Why?
|
| Mannans | 1 | 2023 | 19 | 0.800 |
Why?
|
| Phagocytosis | 11 | 2024 | 263 | 0.790 |
Why?
|
| Anaplasmosis | 1 | 2022 | 5 | 0.760 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2022 | 9 | 0.760 |
Why?
|
| Cell Nucleus | 2 | 2019 | 620 | 0.750 |
Why?
|
| Interferon Type I | 1 | 2024 | 187 | 0.740 |
Why?
|
| Spores, Fungal | 4 | 2020 | 19 | 0.740 |
Why?
|
| Cell Line | 16 | 2020 | 2028 | 0.730 |
Why?
|
| Bias | 1 | 2022 | 112 | 0.720 |
Why?
|
| Microscopy | 2 | 2012 | 91 | 0.700 |
Why?
|
| Staphylococcal Infections | 5 | 2025 | 129 | 0.700 |
Why?
|
| Education, Medical | 2 | 2020 | 180 | 0.700 |
Why?
|
| Calcium | 1 | 2024 | 570 | 0.690 |
Why?
|
| Quality of Life | 3 | 2024 | 1223 | 0.660 |
Why?
|
| Internship and Residency | 6 | 2024 | 797 | 0.640 |
Why?
|
| Microscopy, Confocal | 6 | 2016 | 233 | 0.630 |
Why?
|
| Cryptococcus neoformans | 6 | 2025 | 144 | 0.630 |
Why?
|
| Pneumothorax | 1 | 2019 | 49 | 0.610 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2019 | 244 | 0.600 |
Why?
|
| Vaping | 1 | 2019 | 43 | 0.600 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2008 | 182 | 0.590 |
Why?
|
| Decision Making | 1 | 2022 | 404 | 0.580 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2025 | 557 | 0.560 |
Why?
|
| CARD Signaling Adaptor Proteins | 4 | 2024 | 67 | 0.560 |
Why?
|
| Cell Membrane | 3 | 2019 | 492 | 0.550 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2016 | 115 | 0.540 |
Why?
|
| Ascomycota | 1 | 2017 | 12 | 0.530 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2008 | 144 | 0.520 |
Why?
|
| Syk Kinase | 4 | 2020 | 9 | 0.500 |
Why?
|
| Adaptive Immunity | 2 | 2018 | 101 | 0.500 |
Why?
|
| Virus Shedding | 3 | 2025 | 20 | 0.440 |
Why?
|
| Protein Transport | 5 | 2016 | 400 | 0.440 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2025 | 108 | 0.430 |
Why?
|
| Bacterial Proteins | 7 | 2025 | 760 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 6 | 2025 | 778 | 0.430 |
Why?
|
| West Nile Fever | 1 | 2013 | 5 | 0.410 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 8 | 0.410 |
Why?
|
| Lateral Ventricles | 1 | 2013 | 7 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 10 | 2025 | 3366 | 0.400 |
Why?
|
| Cryptococcosis | 3 | 2011 | 75 | 0.400 |
Why?
|
| Mice, Knockout | 8 | 2019 | 2092 | 0.400 |
Why?
|
| Lysosomes | 4 | 2014 | 167 | 0.400 |
Why?
|
| Cytokines | 7 | 2020 | 926 | 0.400 |
Why?
|
| Inflammation | 5 | 2024 | 1141 | 0.390 |
Why?
|
| Candida | 2 | 2023 | 39 | 0.370 |
Why?
|
| Lung | 5 | 2024 | 938 | 0.370 |
Why?
|
| Antiviral Agents | 2 | 2025 | 321 | 0.370 |
Why?
|
| Aspergillus | 1 | 2011 | 11 | 0.360 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 107 | 0.360 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2011 | 10 | 0.350 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1003 | 0.340 |
Why?
|
| Models, Immunological | 1 | 2010 | 85 | 0.340 |
Why?
|
| Ritonavir | 3 | 2025 | 18 | 0.330 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 87 | 0.330 |
Why?
|
| Awards and Prizes | 3 | 2025 | 34 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 125 | 0.320 |
Why?
|
| Antigen Presentation | 3 | 2018 | 237 | 0.310 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2025 | 202 | 0.310 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 1596 | 0.300 |
Why?
|
| Antigens, CD | 2 | 2007 | 346 | 0.300 |
Why?
|
| Diagnosis, Differential | 4 | 2022 | 966 | 0.290 |
Why?
|
| Fever | 2 | 2022 | 66 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 336 | 0.290 |
Why?
|
| Proguanil | 1 | 2007 | 6 | 0.290 |
Why?
|
| Atovaquone | 1 | 2007 | 5 | 0.280 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2025 | 19 | 0.280 |
Why?
|
| Babesia microti | 1 | 2007 | 7 | 0.280 |
Why?
|
| Babesiosis | 1 | 2007 | 12 | 0.280 |
Why?
|
| Thinking | 2 | 2018 | 27 | 0.280 |
Why?
|
| Membrane Proteins | 4 | 2011 | 892 | 0.280 |
Why?
|
| Societies, Medical | 3 | 2018 | 372 | 0.280 |
Why?
|
| Antifungal Agents | 5 | 2024 | 127 | 0.280 |
Why?
|
| Actinomycosis | 1 | 2006 | 3 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 137 | 0.260 |
Why?
|
| Abdominal Abscess | 1 | 2006 | 13 | 0.260 |
Why?
|
| Acids | 1 | 2006 | 14 | 0.260 |
Why?
|
| H-2 Antigens | 4 | 1995 | 66 | 0.260 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2006 | 50 | 0.250 |
Why?
|
| Endosomes | 1 | 2007 | 178 | 0.250 |
Why?
|
| Alanine | 2 | 2024 | 51 | 0.250 |
Why?
|
| Microtubules | 1 | 2007 | 209 | 0.250 |
Why?
|
| Antigens, Surface | 1 | 2006 | 196 | 0.240 |
Why?
|
| Autophagy | 4 | 2016 | 225 | 0.240 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 260 | 0.240 |
Why?
|
| Immunomodulation | 1 | 2025 | 30 | 0.230 |
Why?
|
| Pseudomonas Infections | 1 | 2025 | 54 | 0.230 |
Why?
|
| Career Mobility | 1 | 2025 | 64 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 45 | 0.230 |
Why?
|
| Phenazines | 1 | 2024 | 10 | 0.220 |
Why?
|
| Leukocyte Elastase | 1 | 2024 | 14 | 0.220 |
Why?
|
| Adenosine Monophosphate | 1 | 2024 | 28 | 0.220 |
Why?
|
| Models, Biological | 3 | 2016 | 1174 | 0.220 |
Why?
|
| Streptococcus pneumoniae | 1 | 2024 | 66 | 0.220 |
Why?
|
| Training Support | 3 | 2018 | 20 | 0.220 |
Why?
|
| Respiratory Mucosa | 1 | 2024 | 53 | 0.220 |
Why?
|
| Endocytosis | 1 | 2025 | 152 | 0.220 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 119 | 0.220 |
Why?
|
| Membrane Transport Proteins | 3 | 2024 | 135 | 0.220 |
Why?
|
| Chemokines | 1 | 2024 | 93 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2024 | 77 | 0.210 |
Why?
|
| NADPH Oxidases | 2 | 2014 | 69 | 0.210 |
Why?
|
| Bacteremia | 1 | 2024 | 94 | 0.210 |
Why?
|
| Benchmarking | 1 | 2024 | 137 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2024 | 136 | 0.210 |
Why?
|
| Education, Medical, Graduate | 2 | 2024 | 348 | 0.210 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 664 | 0.210 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 61 | 0.200 |
Why?
|
| Job Syndrome | 1 | 2023 | 2 | 0.200 |
Why?
|
| Drug Resistance, Viral | 1 | 2024 | 157 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 185 | 0.200 |
Why?
|
| SAIDS Vaccines | 1 | 2022 | 20 | 0.200 |
Why?
|
| Virus Cultivation | 1 | 2022 | 19 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2016 | 450 | 0.190 |
Why?
|
| Psychometrics | 1 | 2024 | 376 | 0.190 |
Why?
|
| Myalgia | 1 | 2022 | 2 | 0.190 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2022 | 22 | 0.190 |
Why?
|
| AIDS Vaccines | 1 | 2022 | 70 | 0.190 |
Why?
|
| Symptom Assessment | 1 | 2022 | 46 | 0.190 |
Why?
|
| Ciprofloxacin | 1 | 2021 | 26 | 0.190 |
Why?
|
| Monocytes | 2 | 2014 | 353 | 0.180 |
Why?
|
| Diarrhea | 1 | 2022 | 76 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 69 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 98 | 0.180 |
Why?
|
| Mammals | 1 | 2023 | 216 | 0.180 |
Why?
|
| Peptides | 3 | 1994 | 571 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2014 | 318 | 0.180 |
Why?
|
| O Antigens | 1 | 2020 | 5 | 0.170 |
Why?
|
| Cholera | 1 | 2020 | 12 | 0.170 |
Why?
|
| Vibrio cholerae | 1 | 2020 | 18 | 0.170 |
Why?
|
| Cells, Cultured | 6 | 2010 | 2140 | 0.170 |
Why?
|
| Naphthols | 1 | 2020 | 3 | 0.170 |
Why?
|
| Transcriptome | 1 | 2023 | 387 | 0.160 |
Why?
|
| Virus Replication | 1 | 2022 | 317 | 0.160 |
Why?
|
| Nobel Prize | 1 | 2020 | 12 | 0.160 |
Why?
|
| Retinopathy of Prematurity | 1 | 2000 | 13 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 19 | 0.160 |
Why?
|
| Male | 13 | 2025 | 29707 | 0.160 |
Why?
|
| Cough | 1 | 2022 | 182 | 0.160 |
Why?
|
| TRPV Cation Channels | 1 | 2020 | 20 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 23 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2019 | 468 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 42 | 0.160 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2000 | 38 | 0.160 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 1647 | 0.160 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 181 | 0.160 |
Why?
|
| Chest Tubes | 1 | 2019 | 17 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 718 | 0.160 |
Why?
|
| Patient Care | 1 | 2020 | 80 | 0.160 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 84 | 0.160 |
Why?
|
| Endoplasmic Reticulum | 2 | 2019 | 173 | 0.160 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 54 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 174 | 0.150 |
Why?
|
| Middle Aged | 7 | 2025 | 17489 | 0.150 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 114 | 0.150 |
Why?
|
| Membrane Microdomains | 1 | 2019 | 49 | 0.150 |
Why?
|
| Salmonella typhimurium | 2 | 2012 | 82 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 860 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2016 | 659 | 0.150 |
Why?
|
| Drainage | 1 | 2019 | 154 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 422 | 0.150 |
Why?
|
| Gene Knockout Techniques | 2 | 2016 | 93 | 0.150 |
Why?
|
| Education | 1 | 2018 | 68 | 0.150 |
Why?
|
| Hematology | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2018 | 5 | 0.140 |
Why?
|
| Phagocytes | 1 | 2018 | 52 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2025 | 117 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1458 | 0.140 |
Why?
|
| N-Formylmethionine | 2 | 2000 | 3 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2018 | 89 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 637 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2024 | 933 | 0.140 |
Why?
|
| Tetraspanin 30 | 2 | 2007 | 2 | 0.130 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 2007 | 5 | 0.130 |
Why?
|
| Hyphae | 1 | 2017 | 16 | 0.130 |
Why?
|
| CD36 Antigens | 1 | 2017 | 26 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 208 | 0.130 |
Why?
|
| Carbohydrates | 1 | 2017 | 39 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 222 | 0.130 |
Why?
|
| Female | 11 | 2025 | 32654 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 217 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 488 | 0.130 |
Why?
|
| Integrin alphaV | 1 | 2016 | 2 | 0.130 |
Why?
|
| Protein Kinase C-delta | 1 | 2016 | 7 | 0.130 |
Why?
|
| Psoriasis | 1 | 2016 | 55 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Point-of-Care Testing | 1 | 2016 | 43 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 430 | 0.120 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2015 | 19 | 0.120 |
Why?
|
| Thrombosis | 1 | 2018 | 199 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 58 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 316 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 26 | 0.120 |
Why?
|
| Receptors, Mitogen | 1 | 2015 | 7 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2016 | 43 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 173 | 0.120 |
Why?
|
| Asthma | 1 | 2020 | 439 | 0.120 |
Why?
|
| Bone Marrow Cells | 3 | 2020 | 237 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2016 | 262 | 0.120 |
Why?
|
| Salmonella Infections | 1 | 2015 | 42 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 668 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2016 | 76 | 0.110 |
Why?
|
| United States | 6 | 2025 | 7782 | 0.110 |
Why?
|
| Macrophages, Alveolar | 2 | 2013 | 64 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 221 | 0.110 |
Why?
|
| Interleukin-1 | 1 | 2015 | 156 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 176 | 0.110 |
Why?
|
| Cross Infection | 1 | 2016 | 161 | 0.110 |
Why?
|
| Vitamin A | 1 | 2014 | 27 | 0.110 |
Why?
|
| Candida glabrata | 1 | 2014 | 2 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2014 | 32 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 2167 | 0.110 |
Why?
|
| Ubiquitin | 2 | 2012 | 97 | 0.110 |
Why?
|
| Chimera | 1 | 1994 | 42 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 767 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 429 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2015 | 111 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2014 | 104 | 0.100 |
Why?
|
| West Nile virus | 1 | 2013 | 6 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2010 | 694 | 0.100 |
Why?
|
| Confusion | 1 | 2013 | 17 | 0.100 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 1995 | 408 | 0.100 |
Why?
|
| Encephalitis | 1 | 2013 | 34 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 573 | 0.100 |
Why?
|
| HeLa Cells | 2 | 2012 | 533 | 0.100 |
Why?
|
| Aged | 5 | 2025 | 14335 | 0.100 |
Why?
|
| Alcoholism | 1 | 2016 | 317 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 761 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 723 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2013 | 379 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2025 | 3272 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 399 | 0.090 |
Why?
|
| Cellulases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Fusariosis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Microspheres | 1 | 2011 | 56 | 0.090 |
Why?
|
| Fusarium | 1 | 2011 | 9 | 0.090 |
Why?
|
| Moths | 1 | 2011 | 26 | 0.090 |
Why?
|
| Adult | 8 | 2025 | 16723 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 6219 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 129 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 135 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1337 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 546 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 216 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2010 | 65 | 0.090 |
Why?
|
| Surface Properties | 1 | 2011 | 278 | 0.090 |
Why?
|
| Jurkat Cells | 1 | 2010 | 109 | 0.090 |
Why?
|
| Tetracycline | 2 | 2024 | 24 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 2597 | 0.090 |
Why?
|
| Intracellular Membranes | 1 | 2010 | 50 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2015 | 702 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 126 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 230 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2011 | 125 | 0.080 |
Why?
|
| Cell Communication | 1 | 2010 | 130 | 0.080 |
Why?
|
| Hypertension | 2 | 2013 | 584 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 176 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2000 | 181 | 0.080 |
Why?
|
| Time Factors | 4 | 2024 | 3752 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 1995 | 1980 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2024 | 159 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 337 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 658 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2006 | 255 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 317 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2010 | 619 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 77 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 831 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 488 | 0.070 |
Why?
|
| Nocodazole | 1 | 2007 | 15 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2007 | 165 | 0.070 |
Why?
|
| Polymers | 1 | 2010 | 319 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 1544 | 0.070 |
Why?
|
| Cell Compartmentation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Methylmercury Compounds | 1 | 2007 | 1 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2666 | 0.070 |
Why?
|
| Actinomyces | 1 | 2006 | 2 | 0.070 |
Why?
|
| Membrane Fusion | 1 | 2006 | 65 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 2006 | 30 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2011 | 491 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 33 | 0.060 |
Why?
|
| Microbial Viability | 2 | 2017 | 54 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 51 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 2554 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2007 | 146 | 0.060 |
Why?
|
| Kidney | 1 | 2008 | 441 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2016 | 23 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 130 | 0.060 |
Why?
|
| Sputum | 1 | 2025 | 37 | 0.060 |
Why?
|
| Salmonella Infections, Animal | 1 | 2005 | 10 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 33 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 1995 | 1583 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 263 | 0.060 |
Why?
|
| Immunity, Mucosal | 1 | 2005 | 51 | 0.060 |
Why?
|
| Coinfection | 1 | 2025 | 58 | 0.060 |
Why?
|
| Streptolysins | 1 | 2024 | 10 | 0.060 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2024 | 14 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 457 | 0.060 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2024 | 22 | 0.060 |
Why?
|
| Species Specificity | 1 | 2025 | 334 | 0.060 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2024 | 28 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 279 | 0.060 |
Why?
|
| Nafcillin | 1 | 2024 | 2 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2024 | 12 | 0.050 |
Why?
|
| Oxacillin | 1 | 2024 | 5 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 620 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2004 | 19 | 0.050 |
Why?
|
| Viral Load | 1 | 2025 | 228 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2025 | 276 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 254 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 57 | 0.050 |
Why?
|
| Education, Graduate | 1 | 2023 | 16 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 45 | 0.050 |
Why?
|
| Kinetics | 2 | 2024 | 759 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 317 | 0.050 |
Why?
|
| Protein Binding | 4 | 2017 | 1595 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2025 | 268 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 115 | 0.050 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2022 | 4 | 0.050 |
Why?
|
| England | 2 | 2000 | 28 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 18 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2005 | 245 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 106 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2022 | 51 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 120 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2023 | 267 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2023 | 70 | 0.050 |
Why?
|
| Vero Cells | 1 | 2022 | 78 | 0.050 |
Why?
|
| Mupirocin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2021 | 19 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1252 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 109 | 0.040 |
Why?
|
| Virulence | 2 | 2011 | 191 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 410 | 0.040 |
Why?
|
| Animals, Suckling | 1 | 2020 | 2 | 0.040 |
Why?
|
| Agglutination | 1 | 2020 | 5 | 0.040 |
Why?
|
| Biomarkers | 1 | 2006 | 1391 | 0.040 |
Why?
|
| Bangladesh | 1 | 2020 | 20 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 107 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 205 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 321 | 0.040 |
Why?
|
| Survival Rate | 2 | 2000 | 845 | 0.040 |
Why?
|
| Cosmetic Techniques | 1 | 2020 | 11 | 0.040 |
Why?
|
| Bronchioles | 1 | 2020 | 5 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 542 | 0.040 |
Why?
|
| Return to Work | 1 | 2020 | 25 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2020 | 32 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 148 | 0.040 |
Why?
|
| Allergens | 1 | 2020 | 53 | 0.040 |
Why?
|
| Extracellular Traps | 1 | 2020 | 43 | 0.040 |
Why?
|
| Calcineurin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2000 | 70 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 103 | 0.040 |
Why?
|
| Immunization | 1 | 2000 | 124 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 362 | 0.040 |
Why?
|
| Gestational Age | 1 | 2000 | 189 | 0.040 |
Why?
|
| Risk Factors | 3 | 2020 | 5324 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2000 | 78 | 0.040 |
Why?
|
| Charities | 1 | 2018 | 3 | 0.040 |
Why?
|
| Foundations | 1 | 2018 | 9 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 495 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 158 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunological Synapses | 1 | 2018 | 10 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 366 | 0.040 |
Why?
|
| Microscopy, Atomic Force | 1 | 2018 | 31 | 0.040 |
Why?
|
| Perforin | 1 | 2018 | 31 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1369 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 52 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 486 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 178 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2018 | 109 | 0.030 |
Why?
|
| Mentors | 1 | 2018 | 119 | 0.030 |
Why?
|
| Centralized Hospital Services | 1 | 1997 | 6 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2017 | 67 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 49 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 156 | 0.030 |
Why?
|
| Physical Examination | 1 | 2017 | 111 | 0.030 |
Why?
|
| Chloroquine | 1 | 2017 | 61 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 414 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 190 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Mucorales | 1 | 2016 | 1 | 0.030 |
Why?
|
| Integrin beta3 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2016 | 10 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 10 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 2016 | 29 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1271 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 345 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 695 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 124 | 0.030 |
Why?
|
| Students, Medical | 1 | 2018 | 261 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2000 | 1346 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 1995 | 5 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2000 | 405 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 172 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1993 | 369 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 449 | 0.030 |
Why?
|
| Salmonella | 1 | 2015 | 44 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 606 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1538 | 0.030 |
Why?
|
| Child | 2 | 2022 | 4502 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 129 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 35 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 446 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 119 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 1993 | 34 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5630 | 0.030 |
Why?
|
| Critical Care | 1 | 1997 | 397 | 0.030 |
Why?
|
| Zymosan | 1 | 2013 | 25 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 476 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1992 | 69 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 362 | 0.020 |
Why?
|
| Glycine | 1 | 1992 | 48 | 0.020 |
Why?
|
| Motion | 1 | 1992 | 59 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 668 | 0.020 |
Why?
|
| Temperature | 1 | 1994 | 306 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 731 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 369 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 979 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 139 | 0.020 |
Why?
|
| Base Sequence | 1 | 1994 | 1322 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1991 | 131 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 669 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 670 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 42 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2010 | 40 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2010 | 23 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 964 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 148 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 318 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 226 | 0.020 |
Why?
|
| Proteinuria | 1 | 2008 | 41 | 0.020 |
Why?
|
| Albuminuria | 1 | 2008 | 31 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1609 | 0.020 |
Why?
|
| Mitochondria | 1 | 1991 | 361 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2008 | 90 | 0.020 |
Why?
|
| Developing Countries | 1 | 2008 | 94 | 0.020 |
Why?
|
| Social Behavior | 1 | 2008 | 90 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 6602 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 1192 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 52 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1738 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2154 | 0.020 |
Why?
|
| Hair | 1 | 2007 | 82 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 364 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 435 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 451 | 0.010 |
Why?
|
| Mental Health | 1 | 2008 | 370 | 0.010 |
Why?
|
| Chemokines, CX3C | 1 | 2005 | 4 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 4669 | 0.010 |
Why?
|
| Chemokine CX3CL1 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Ileum | 1 | 2005 | 22 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 295 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 204 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 53 | 0.010 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2005 | 13 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 538 | 0.010 |
Why?
|
| Peyer's Patches | 1 | 2005 | 35 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2006 | 324 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2005 | 79 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2004 | 30 | 0.010 |
Why?
|
| Hydrazones | 1 | 2004 | 5 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 77 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 68 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 886 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 128 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 203 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 81 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 303 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 94 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 126 | 0.010 |
Why?
|
| Catalysis | 1 | 2004 | 160 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 135 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 523 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 179 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 1963 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2452 | 0.010 |
Why?
|
| Formates | 2 | 1993 | 2 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 500 | 0.010 |
Why?
|
| Protein Folding | 1 | 2004 | 267 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 262 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 431 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1530 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2000 | 99 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 59 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 2324 | 0.010 |
Why?
|
| Victoria | 1 | 1997 | 7 | 0.010 |
Why?
|
| Mortality | 1 | 1997 | 159 | 0.010 |
Why?
|
| Patient Admission | 1 | 1997 | 194 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1997 | 204 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1997 | 765 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 1994 | 1 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1994 | 63 | 0.010 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 1993 | 3 | 0.010 |
Why?
|
| Alkylation | 1 | 1993 | 10 | 0.010 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1993 | 17 | 0.010 |
Why?
|
| Logistic Models | 1 | 1997 | 1270 | 0.010 |
Why?
|
| Nucleocapsid Proteins | 1 | 1993 | 34 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1993 | 31 | 0.010 |
Why?
|
| Length of Stay | 1 | 1997 | 806 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1993 | 116 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1993 | 132 | 0.010 |
Why?
|
| Epitopes | 1 | 1993 | 289 | 0.010 |
Why?
|
| Infant | 1 | 1997 | 1640 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1997 | 1980 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 189 | 0.010 |
Why?
|